The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension
Open accessAbstract
The numerous controlled clinical trials performed recently in pulmonary arterial hypertension (PAH) can allow us to abandon a clinical-based treatment strategy and adopt an evidence-based therapy. Both uncontrolled and controlled clinical trials with different compounds and procedures are reviewed and compared in order to define the efficacy-to-side-effect ratio of each treatment. A grading system for the level of evidence of treatments based on the number of favorable controlled clinical trials performed with a given compound is adopted; a treatment algorithm based on the evidence derived by clinical trials is proposed. It includes drugs approved by regulatory agencies for the treatment of patients with PAH and/or drugs available on the market for other indications. The algorithm is restricted to patients in New York Heart Association (NYHA) functional class III or IV because they represent the largest population included in controlled clinical trials. In addition, the different treatments have been evaluated mainly in sporadic, idiopathic PAH and in PAH associated with scleroderma or to anorexigen use. Extrapolation of these recommendations to the other PAH subgroups should be done with caution. Oral anticoagulation is proposed for all patients, whereas diuretic treatment and supplemental oxygen are indicated in cases of fluid retention and hypoxemia, respectively. High doses of calcium channel blockers are indicated only in the minority of patients who are responders to acute vasoreactivity testing. Nonresponders to acute vasoreactivity testing, or responders who remain in NYHA functional class III, should be considered candidates for treatment with either an endothelin receptor antagonist or a prostanoid. Continuous intravenous administration of epoprostenol is proposed as rescue treatment in NYHA functional class IV patients. Phosphodiesterase-V inhibitors should be considered in patients who have failed or are not candidates to other therapies. Combination therapy can be attempted in selected cases. Both balloon atrial septostomy and lung transplantation are indicated for refractory patients or where medical treatment is unavailable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
Self-citationBarst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
Self-citationInhaled Iloprost for Severe Pulmonary Hypertension
Olschewski, H., Simonneau, G., Galiè, N., Higenbottam, T., Naeije, R., Rubin, L. J., Nikkho, S., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783
Self-citationPrimary Pulmonary Hypertension
Rubin, L. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360207 · Cited by 1,726
Self-citationThe Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
Rich, S., Kaufmann, E., & Levy, P. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270203 · Cited by 1,550
SIMONNEAU, G., BARST, R. J., GALIE, N., NAEIJE, R., RICH, S., BOURGE, R. C., KEOGH, A., OUDIZ, R., FROST, A., BLACKBURN, S. D., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.6.2106079 · Cited by 1,441
Self-citationBadesch, D. B., Tapson, V. F., McGoon, M. D., Brundage, B. H., Rubin, L. J., Wigley, F. M., Rich, S., Barst, R. J., Barrett, P. S., Kral, K. M., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-6-200003210-00002 · Cited by 1,075
Self-citationPrimary pulmonary hypertension: natural history and the importance of thrombosis.
Fuster, V, Steele, P. M., Edwards, W. D., Gersh, B. J., McGoon, M. D., & Frye, R. L. (1984) · Circulation · doi:10.1161/01.cir.70.4.580 · Cited by 1,066
Rubin, L. J., Mendoza, J., Hood, M., McGoon, M., Barst, R., Williams, W. B., Diehl, J. H., Crow, J., & Long, W. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-7-485 · Cited by 706
Self-citationGaliè, N., Humbert, M., Vachiéry, J.-L., Vizza, C., Kneussl, M., Manes, A., Sitbon, O., Torbicki, A., Delcroix, M., Naeije, R., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01786-2 · Cited by 648
Self-citationBeraprost therapy for pulmonary arterial hypertension
Barst, R. J., McGoon, M., McLaughlin, V., Tapson, V., Oudiz, R., Shapiro, S., Robbins, I. M., Channick, R., Badesch, D., Rayburn, B. K., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00463-7 · Cited by 631
The double-blind, randomized, placebo-controlled trial
Kaptchuk, T. J. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00347-4 · Cited by 595
Clinical efficacy of sildenafil in primary pulmonary hypertension
Sastry, B. K. S., Narasimhan, C., Reddy, N. K., & Raju, B. S. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.10.056 · Cited by 488
Vasodilator Therapy for Primary Pulmonary Hypertension in Children
Barst, R. J., Maislin, G., & Fishman, A. P. (1999) · Circulation · doi:10.1161/01.cir.99.9.1197 · Cited by 427
Jego, P. (1996) · La Revue de Médecine Interne · doi:10.1016/0248-8663(96)83752-0 · Cited by 409
Galiè, N., Hinderliter, A. L., Torbicki, A., Fourme, T., Simonneau, G., Pulido, T., Espinola-Zavaleta, N., Rocchi, G., Manes, A., Frantz, R., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00121-9 · Cited by 378
Self-citationGhofrani, H. A., Rose, F., Schermuly, R. T., Olschewski, H., Wiedemann, R., Kreckel, A., Weissmann, N., Ghofrani, S., Enke, B., Seeger, W., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00555-2 · Cited by 365
Self-citationHertz, M. I., Taylor, D. O., Trulock, E. P., Boucek, M. M., Mohacsi, P. J., Edwards, L. B., & Keck, B. M. (2002) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(02)00498-9 · Cited by 360
Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension
Sandoval, J., Gaspar, J., Pulido, T., Bautista, E., Martínez-Guerra, M. L., Zeballos, M., Palomar, A., & Gómez, A. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00238-1 · Cited by 356
Sildenafil in Primary Pulmonary Hypertension
Prasad, S., Wilkinson, J., & Gatzoulis, M. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431814 · Cited by 337
Barst, R. J., Rich, S., Widlitz, A., Horn, E. M., McLaughlin, V., & McFarlin, J. (2002) · Chest · doi:10.1378/chest.121.6.1860 · Cited by 241
Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension
McLaughlin, V. V., Gaine, S. P., Barst, R. J., Oudiz, R. J., Bourge, R. C., Frost, A., Robbins, I. M., Tapson, V. F., McGoon, M. D., Badesch, D. B., et al. (2003) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200302000-00019 · Cited by 232
Self-citationNocturnal Oxygen Therapy in Patients with the Eisenmenger Syndrome
SANDOVAL, J., AGUIRRE, J. S., PULIDO, T., MARTINEZ-GUERRA, M. L., SANTOS, E., ALVARADO, P., ROSAS, M., & BAUTISTA, E. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.9.2106076 · Cited by 213
Hoeper, M. M., Taha, N., Bekjarova, A., Gatzke, R., & Spiekerkoetter, E. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00008003 · Cited by 201
Bhatia, S., Frantz, R. P., Severson, C. J., Durst, L. A., & McGoon, M. D. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.10.1207 · Cited by 122
Channick, R. N., Badesch, D. B., Tapson, V. F., et al. (2001) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(00)00606-9 · Cited by 112
Cited by
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,476
Self-citationACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,360
Self-citationWriting Committee Members, McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192230 · Cited by 1,093
Self-citationGaliè, N., Olschewski, H., Oudiz, R. J., Torres, F., Frost, A., Ghofrani, H. A., Badesch, D. B., McGoon, M. D., McLaughlin, V. V., Roecker, E. B., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.742510 · Cited by 1,083
Self-citationRisk stratification and medical therapy of pulmonary arterial hypertension
Galiè, N., Channick, R. N., Frantz, R. P., Grünig, E., Jing, Z. C., Moiseeva, O., Preston, I. R., Pulido, T., Safdar, Z., Tamura, Y., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01889-2018 · Cited by 819
Self-citation
Metadata
- Authors
- Galiè, N., Seeger, W., Naeije, R., Simonneau, G., & Rubin, L. J.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2004-06
- Volume
- 43
- Issue
- 12
- Pages
- S81-S88
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W1970369512
- Cited by
- 255
- References
- 26
- FWCI
- 32.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.